Goldman Sachs Sees 40% Upside In GW Pharmaceuticals

Shares of cannabinoid-focused biotech company GW Pharmaceuticals PLC- ADR GWPH are "on a path to new highs," according to Goldman Sachs.

The Analyst

Goldman Sachs analyst Salveen Richter upgraded GW Pharma from Neutral to Buy and lifted her price target to $174, suggesting roughly 40 percent upside from current levels.

The Thesis

Richter premised the upgrade on five factors, namely clobazam drug-drug interaction data presented at the American Epilepsy Society meeting, positive KOL feedback, compelling Phase 3 efficacy data for Epidiolex in Dravet Syndrome, and Lennox-Gaustaut Syndrome, significant demand for off-label use and multiple 2018 pipeline catalysts.

Clobazam drug-drug interaction data from Phase 3 studies in DS/LGS presented at the AES meeting held Dec. 1-5 indicated that Epidiolex's effect is independent and synergistic with clobazam co-therapy, Goldman said.

Key opinion leaders are positive on Epidiolex adoption and launch trajectory, Richter said. Apart from being impressed with the compelling efficacy relayed by the Phase 3 studies, physicians view Epidiolex as a novel and differentiated AED, she added.

"KOLs also noted high pre-existing interest and awareness of Epidiolex among patients and carers will likely translate into strong launch demand," Richter said.

Goldman expects a June 2018 PDUFA date, and up to 90 days for DEA rescheduling, which suggests a third quarter or fourth quarter launch. This follows the company rolling the NDA in October. Goldman estimates 2025 worldwide peak sales of $2.2 billion, of which 56 percent is expected to be derived from off-label use.

Goldman also sees pipeline optionality from additional studies. Some of the studies underway include:

  • Phase 2/3 data in infantile spasms due in the first quarter of 2018
  • Phase 3 dose-ranging data in DS in the second-half of 2018
  • Phase 3 data in tuberculosis sclerosis complex due in the second-half of 2018
  • CBDV Phase 2 data in adult-onset partial epilepsy due in the first quarter of 2018
  • Phase 2 initiation in autism spectrum disorders, expected in the first-half of 2018

"We also look to patent application decisions for Epidiolex which may extend protection beyond the 7.5/12-year exclusivity in the US/EU," Goldman said.

Price Action

The shares of GW Pharma are up over 15 percent in the year-to-date period. At time of writing, the stock was up 4.7 percent to $129.89.

Related Links:

Guy Adami Is Bullish On GW Pharmaceuticals

How to Invest In Marijuana Stocks

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesPrice TargetTop StoriesAnalyst RatingsEpidiolexGoldman SachsSalveen Richter
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!